<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112462</url>
  </required_header>
  <id_info>
    <org_study_id>SC02009</org_study_id>
    <secondary_id>2009-018093-55</secondary_id>
    <nct_id>NCT01112462</nct_id>
  </id_info>
  <brief_title>To Test Bioequivalence Between Two Formulations of Paracetamol/Phenylephrine</brief_title>
  <official_title>A Single-dose, Randomized, Crossover Bioequivalence Study to Compare Two Formulations of Paracetamol/Phenylephrine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess bioequivalence between two paracetamol/ phenylephrine
      combination products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a single dose, randomized, two-way crossover study in 40 healthy subjects,
      with equal numbers of males and females. Drop-outs will not be replaced. The two doses of
      medication given in the study (a single dose in each of the two study periods) will be
      separated by a washout period of at least 7 days. In each study period, sixteen blood samples
      for pharmacokinetic analysis will be taken over 24 hours. Blood samples will be centrifuged
      and concentrations of paracetamol and phenylephrine in plasma will be measured using a
      validated chromatographic assay. Pharmacokinetic parameters will be calculated from plasma
      concentration data. The rate and extent of absorption of the formulations will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic measurements</measure>
    <time_frame>during 24 hours following drug administration</time_frame>
    <description>Pharmacokinetic measurements including:
Cmax (Maximum concentration)
AUC0-t (Area under the plasma concentration versus time curve from 0h to the lastmeasurable concentration)
AUC0-inf (Area under the plasma concentration versus time curve from 0h to infinity)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol 500 mg/Phenylephrine 5 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sachet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paracetamol 1000 mg/Phenylephrine 10 mg sachet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 500 mg/Phenylephrine 5 mg tablets</intervention_name>
    <description>2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period</description>
    <arm_group_label>Tablet</arm_group_label>
    <other_name>Sudafed PE Sinus Pain Relief™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 1000 mg/Phenylephrine 10 mg sachet</intervention_name>
    <description>1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period</description>
    <arm_group_label>Sachet</arm_group_label>
    <other_name>Flu Plus Hot Lemon™ sachet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female

          -  Caucasians

          -  Aged between 18 and 50 years

          -  BMI ≤ 30 kg/m2

          -  Clinically normal medical history

          -  Physical normal examination

          -  Normal laboratory test results

        Exclusion Criteria:

          -  Pregnancy, lactation or intended pregnancy

          -  Hypersensitivity to or intolerant of the study medications

          -  Donation or loss of blood within 90 days preceding the first dose of study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Kruse, PhD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shandon Clinical Trials Ltd.</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasal congestion, Headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

